Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Fineline Cube Aug 5, 2026
Company Deals

Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants

Fineline Cube Nov 9, 2022

China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused...

Company Drug

Cyramza Prescribed in China for Advanced Gastric Cancer

Fineline Cube Nov 9, 2022

Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...

Company Deals

Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization

Fineline Cube Nov 9, 2022

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...

Company Drug

Merck’s Keytruda Receives 10th Indication Approval in China for TNBC

Fineline Cube Nov 9, 2022

US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...

Company Deals

Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...

Company Deals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

Fineline Cube Nov 8, 2022

Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD...

Company

Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance

Fineline Cube Nov 8, 2022

Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...

Company Deals

Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE

Fineline Cube Nov 8, 2022

Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607,...

Company Deals

SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round

Fineline Cube Nov 8, 2022

China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million)...

Company Deals Digital

PingAn Good Doctor Partners with Roche and OrigiMed at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...

Company Deals Digital

Organon Partners with Alibaba Health to Enhance Chronic Disease Management

Fineline Cube Nov 8, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study

Fineline Cube Nov 8, 2022

China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...

Company Deals

Organon Sponsors Retail Pharmacy Health Center at CIIE

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm...

Company Deals

Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare

Fineline Cube Nov 8, 2022

The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership...

Company Deals

Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China

Fineline Cube Nov 8, 2022

Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...

Company Deals

Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...

Company

BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit

Fineline Cube Nov 7, 2022

Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to...

Company

Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline

Fineline Cube Nov 7, 2022

US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health...

Company Deals

Organon Signs MOU with China’s National Health Commission at CIIE

Fineline Cube Nov 7, 2022

Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...

Company Drug

Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD

Fineline Cube Nov 7, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...

Posts pagination

1 … 642 643 644 … 704

Recent updates

  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
  • Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
  • Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Company

Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline

Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.